Abstract
Infusion pump-based therapies are an effective treatment option for patients with advanced Parkinson´s disease. Achieving monotherapy with infusion-based therapies could simplify the treatment regimen, provide better medication adherence, reduce adverse events and drug interactions. This review presents the literature data on the efficacy, safety, and achievability of monotherapy with all available infusion-based therapies, including apomorphine, levodopa-carbidopa-intestinal gel (LCIG), levodopa-entacapone-carbidopa intestinal gel (LECIG), and foslevodopa-foscarbidopa (LDp/CDp). In summary, monotherapy is achievable and effective in most patients on intestinal levodopa infusion therapy and in some patients on apomorphine infusion. There is a need for further investigation of monotherapy compared to polytherapy, especially in new pump treatment options (LECIG and LDp/CDp). Future research should reveal which patients on infusion-based therapies could benefit from monotherapy, including identification of potential baseline predictors of achieving monotherapy in patients treated with specific infusion-based therapies.
This is a preview of subscription content, log in via an institution to check access.
References
Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1
Aldred J, Henriksen T, Bouchard M, Martínez-Castrillo J, Soileau M, Spiegel A et al (2023b) Efficacy and safety of foslevodopa/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson’s disease [abstract]. Mov Disord 38 (suppl 1)
Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P (2017) GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018
Antonini A, Odin P, Pahwa R et al (2021) The long-term impact of levodopa/carbidopa intestinal gel on ’of’-time in patients with advanced Parkinson’s disease: a systematic review. Adv Ther 38:2854–2890. https://doi.org/10.1007/s12325-021-01747-1
Antonini and Jenner (2018) Apomorphine infusion in advanced Parkinson disease. Nat Rev Neurol 14:693–694. https://doi.org/10.1038/s41582-018-0083-y
Bastide MF, Meissner WG, Picconi B et al (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Progr Neurobiol 132:96–168. https://doi.org/10.1016/j.pneurobio.2015.07.002
Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F (2017) Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. Clin Nucl Med 42:83–87. https://doi.org/10.1097/rlu.0000000000001470
Borgemeester RWK, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Parkinsonism Relat Disord 23:17–22. https://doi.org/10.1016/j.parkreldis.2015.11.013
Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H (2017) Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm 124(2). https://doi.org/10.1007/s00702-017-1698-7
Chaudhuri KR, Rizos A, Sethi KD (2013) Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm 120:1305–1320. https://doi.org/10.1007/s00702-013-0981-5
Desjardins C, Nilles C, Devos D, Roze E (2023) Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option? J Mov Disord. 2023;16(3):328–330. https://doi.org/10.14802/jmd.23057
Deuschl G, Antonini A, Costa J, Śmiłowska K, Berg D, Corvol JC et al (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the treatment of Parkinson’s Disease: I. Invasive therapies. Mov Disord 37:1360–1374. https://doi.org/10.1002/mds.29066
Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T et al (2009) Neuropathological assessment of Parkinson´s disease. Lancet Neurol 36:1150–1157. https://doi.org/10.1016/s1474-4422(09)70238-8
Dietrichs E, Odin P (2017) Algorithms for the treatment of motor problems in Parkinson’s disease. Acta Neurol Scand 136:378–385. https://doi.org/10.1111/ane.12733
Fabbri M, Ferreira JJ, Rascol O (2022) COMT inhibitors in the management of Parkinson’s disease. CNS Drugs 36:261–282. https://doi.org/10.1007/s40263-021-00888-9
Fabbrini and Guerra (2021) Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia. J Exp Pharmacol 13:469–485. https://doi.org/10.2147/JEP.S265282
Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra P, Marconi S, Gasbarrini A, Bentivoglio AR (2013) The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 28:1241–1249. https://doi.org/10.1002/mds.25522
Fasano A, Gurevich T, Jech R et al (2021) Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov Disord 36:1853–1862. https://doi.org/10.1002/mds.28596
Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33:1248–1266. https://doi.org/10.1002/mds.27372
Freire-Alvarez E, Kurča E, Lopez Manzanares L et al (2021) Levodopa-carbidopa intestinal gel reduces dyskinesia in Parkinson’s disease in a randomized trial. Mov Disord 36:2615–2623. https://doi.org/10.1002/mds.28703
Gancher S, Nutt J (2010) Tolerance to apomorphine develops and reverses rapidly. Mov Disord 25(6):803–804. https://doi.org/10.1002/mds.23036
Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 10(1):37–43. https://doi.org/10.1002/mds.870100108
García Ruiz PJ, Sesar Ignacio A, Ares Pensado B et al (2008) Eficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fuctuations: a multicenter study. Mov Disord 23:1130–1136. https://doi.org/10.1002/mds.22063
Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A (2023) Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience. J Neural Transm 130(11):1475–1484. https://doi.org/10.1007/s00702-023-02686-7
Jenner P, Katzenschlager R (2016) Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord 33(Suppl 1):S13–S21. https://doi.org/10.1016/j.parkreldis.2016.12.003
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17(9):749–759. https://doi.org/10.1016/S1474-4422(18)30239-4
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A (2021) Long-term safety and eficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fuctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 83:79–85. https://doi.org/10.1016/j.parkreldis.2020.12.024
Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH (2020) Motor complications in Parkinson’s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 35:185–190. https://doi.org/10.1002/mds.27882
Kimber TE, Fang J, Hudd LJ, Thompson PD (2017) Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J 47:570–573. https://doi.org/10.1111/imj.13378
Kolmančič K, Zupančič NK, Trošt M et al (2022) Continuous dopaminergic stimulation improves cortical maladaptive changes in advanced Parkinson’s disease. Mov Disord 37:1465–1473. https://doi.org/10.1002/mds.29028
Kurlan R, Rothfield KP, Woodward WR et al (1988) Erratic gastric emptying of levodopa may cause random fluctuations of parkinsonian mobility. Neurology 38:419–421. https://doi.org/10.1212/WNL.38.3.419
Lopiano L, Modugno N, Marano P et al (2019) Motor and nonmotor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: fnal results of the GREENFIELD observational study. J Neurol 266:2164–2176. https://doi.org/10.1007/s00415-019-09337-6
Manson AJ, Turner K, Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 17(6):1235–1241. https://doi.org/10.1111/ane.12733
Martinez-Martin P, Reddy P, Katzenschlager R et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30:510–516. https://doi.org/10.1002/mds.26067
Müller T (2010) Entacapone. Expert Opin Drug Metab Toxicol 6:983–993. https://doi.org/10.1517/17425255.2010.502167
Nilsson D, Hansson LE, Johansson K et al (1998) Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease. Acta Neurol Scand 97:175–183. https://doi.org/10.1111/j.1600-0404.1998.tb00633.x
Nyholm D (2007) The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord 13:S13–S17. https://doi.org/10.1016/j.parkreldis.2007.06.005
Nyholm D, Askmark H, Gomes-Trolin C et al (2003) Optimizing Levodopa Pharmacokinetics: intestinal infusion Versus oral sustained-release tablets. Clin Neuropharmacol 26(3):p156–p163. https://doi.org/10.1097/00002826-200305000-00010. May 2003
Nyholm D, Nilsson Remahl AIM, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223. https://doi.org/10.1212/01.WNL.0000149637.70961.4C
Nyholm and Jost (2022) Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Ther Adv Neurol Disord 15:17562864221108018. https://doi.org/10.1177/17562864221108018
Olanow CR, Stern MB, Sethi K (2009) Scientific and clinical basis for the treatment of Parkinson´s disease. Neurology 72(4):S1–136. https://doi.org/10.1212/WNL.0b013e3181a1d44c
Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, doubleblind, double-dummy study. Lancet Neurol 13:141–149. https://doi.org/10.1016/S1474-4422(13)70293-X
Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for Parkinson’s disease: current status and future opportunities. Mov Disord 35:1731–1744. https://doi.org/10.1002/mds.28215
Öthman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med 11:254. https://doi.org/10.3390/jpm11040254
Pahwa R, Soileau M, Standaert D, Fung V, Kimber T, Malaty I et al (2022) Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa (abstract). Mov Disord 37(2):346
Papuć E, Trzciniecka O, Rejdak K (2019) Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease. Ann Agric Environ Med 2019;26(1):133–137. https://doi.org/10.26444/aaem/99699
Picconi B, Hernández LF, Obeso JA, Calabresi P (2018) Motor complications in Parkinson’s disease: striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord 33:867–876. https://doi.org/10.1002/mds.27261
Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 65:709–716. https://doi.org/10.1136/jnnp.65.5.709
Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W (1988) Subcutaneous apomorphine in Parkinson’s disease. Lancet 1:943. https://doi.org/10.1016/s0140-6736(88)91755-2
Poewe W, Seppi K, Tanner C et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https://doi.org/10.1038/nrdp.2017.13
Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A (2019) Levodopa-carbidopa intestinal gel Monotherapy: GLORIA Registry demographics, efficacy, and Safety. J Parkinson’s Disease 9(3):531–554. https://doi.org/10.3233/JPD-191605
Rosebraugh M, Voight EA, Moussa EM et al (2021) Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson’s disease. Annal Neurol 90:52–61. https://doi.org/10.1002/ana.26073
Rožanković PB, Lasić S (2023) 24-hour levodopa–entacapone–carbidopa intestinal gel may improve disabling dyskinesia: a case report. Annals Mov Disorders 6(3):149–151. https://doi.org/10.4103/aomd.aomd_15_23
Rus T, Premzl M, Križnar NZ et al (2022) Adverse efects of levodopa/carbidopa intrajejunal gel treatment: a single-center longterm follow-up study. Acta Neurol Scand 146:537–544. https://doi.org/10.1111/ane.13675
Schröter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S (2024) Advanced therapies in Parkinson’s disease: an individualized approach to their indication. J Neural Transm 13. https://doi.org/10.1007/s00702-024-02773-3
Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: a randomized crossover study. Mov Disord 32:283–286. https://doi.org/10.1002/mds.26855
Senek M, Nyholm D, Nielsen EI (2020) Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: efects of entacapone infusion and genetic polymorphism. Sci Rep 10:18057. https://doi.org/10.1038/s41598-020-75052-2
Sesar Á, Fernández-Pajarín G, Ares B et al (2017) Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease:10-year experience with 230 patients. J Neurol 264:946–954. https://doi.org/10.1007/s00415-017-8477-0
Soileau MJ, Aldred J, Budur K et al (2022) Safety and efcacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, activecontrolled, phase 3 trial. Lancet Neurol 21:1099–1109. https://doi.org/10.1016/S1474-4422(22)00400-8
Standaert DG, Aldred J, Anca-Herschkovitsch M et al (2021) DUOGLOBE: one-year outcomes in a real-world study of levodopa-carbidopa intestinal gel for Parkinson’s disease. Mov Disord Clin Pract 8:1061–1074. https://doi.org/10.1002/mdc3.13239
Stibe C, Lees A, Stern G (1987) Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-of fuctuations. Lancet 1:871. https://doi.org/10.1016/s0140-6736(87)91660-6
Thakkar S, Fung VSC, Merola A et al (2021) 24-hour levodopa-carbidopa intestinal gel: clinical experience and practical recommendations. CNS Drugs 35:137–149. https://doi.org/10.1007/s40263-020-00782-w
Thaler A, Barer Y, Gross R et al (2022) Long-term persistence and monotherapy with device-aided therapies: a retrospective analysis of an Israeli cohort of patients with Advanced Parkinson’s Disease. Adv Ther 39:2009–2024. https://doi.org/10.1007/s12325-022-02072-x
Tsunemi T, Oyama G, Saiki S et al (2021) Intrajejunal infusion of levodopa/carbidopa for advanced Parkinson’s disease: a systematic review. Mov Disord 36:1759–1771. https://doi.org/10.1002/mds.28595
Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ (2004) A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J Neurol 251(11):1370–1374. https://doi.org/10.1007/s00415-004-0547-4
van Laar T, Postma AG, Drent M (2010) Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson’s disease and pre-existing visual hallucinations. Parkinsonism Relat Disord 16:71–72. https://doi.org/10.1016/j.parkreldis.2009.05.006
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rožanković, P.B., Johansson, A., Péter, K. et al. Monotherapy with infusion therapies – useful or not?. J Neural Transm (2024). https://doi.org/10.1007/s00702-024-02801-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00702-024-02801-2